BioCentury

8:00 AM GMT, Nov 10, 2014
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 11/7 cls
Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) H.C. Wainwright Swayampakula Ramakanth Downgrade Neutral (from buy) -47% C$0.66
Ramakanth downgraded after FDA issued a complete response letter for an NDA for Macrilen macimorelin acetate (AEZS-130) to diagnose adult growth hormone deficiency (GHD). FDA requested the company conduct an additional confirmatory trial plus a QT

Read the full 832 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.